Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1992 1
1993 1
1994 3
1995 1
1996 3
1998 1
1999 1
2000 3
2001 2
2002 2
2003 8
2004 10
2005 4
2006 13
2007 7
2008 13
2009 8
2010 11
2011 13
2012 18
2013 14
2014 20
2015 33
2016 22
2017 31
2018 38
2019 43
2020 28
2021 33
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

331 results
Results by year
Filters applied: . Clear all
Page 1
Showing results for paulo salvage
Search for Paulo Savaget instead (2 results)
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium.
Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC, Mer M, Pana ZD, Seidel D, Sheppard DC, Wahba R, Akova M, Alanio A, Al-Hatmi AMS, Arikan-Akdagli S, Badali H, Ben-Ami R, Bonifaz A, Bretagne S, Castagnola E, Chayakulkeeree M, Colombo AL, Corzo-León DE, Drgona L, Groll AH, Guinea J, Heussel CP, Ibrahim AS, Kanj SS, Klimko N, Lackner M, Lamoth F, Lanternier F, Lass-Floerl C, Lee DG, Lehrnbecher T, Lmimouni BE, Mares M, Maschmeyer G, Meis JF, Meletiadis J, Morrissey CO, Nucci M, Oladele R, Pagano L, Pasqualotto A, Patel A, Racil Z, Richardson M, Roilides E, Ruhnke M, Seyedmousavi S, Sidharthan N, Singh N, Sinko J, Skiada A, Slavin M, Soman R, Spellberg B, Steinbach W, Tan BH, Ullmann AJ, Vehreschild JJ, Vehreschild MJGT, Walsh TJ, White PL, Wiederhold NP, Zaoutis T, Chakrabarti A; Mucormycosis ECMM MSG Global Guideline Writing Group. Cornely OA, et al. Lancet Infect Dis. 2019 Dec;19(12):e405-e421. doi: 10.1016/S1473-3099(19)30312-3. Epub 2019 Nov 5. Lancet Infect Dis. 2019. PMID: 31699664 Free PMC article. Review.
First-line treatment with high-dose liposomal amphotericin B is strongly recommended, while intravenous isavuconazole and intravenous or delayed release tablet posaconazole are recommended with moderate strength. Both triazoles are strongly recommended salvage treatments. …
First-line treatment with high-dose liposomal amphotericin B is strongly recommended, while intravenous isavuconazole and intravenous or del …
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Döhner H, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Adès L, Avvisati G, Montesinos P, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F. Sanz MA, et al. Blood. 2019 Apr 11;133(15):1630-1643. doi: 10.1182/blood-2019-01-894980. Epub 2019 Feb 25. Blood. 2019. PMID: 30803991 Free PMC article. Review.
Together with providing current indications on genetic diagnosis, modern risk-adapted frontline therapy, and salvage treatment, the review contains specific recommendations for the identification and management of the most important complications such as the bleedin …
Together with providing current indications on genetic diagnosis, modern risk-adapted frontline therapy, and salvage treatment …
Novel therapeutic choices in immune aplastic anemia.
Scheinberg P. Scheinberg P. F1000Res. 2020 Sep 10;9:F1000 Faculty Rev-1118. doi: 10.12688/f1000research.22214.1. eCollection 2020. F1000Res. 2020. PMID: 32953089 Free PMC article. Review.
Since the 1970s, hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy (IST) have changed SAA's natural history by improving marrow function and pancytopenia. ...The introduction of eltrombopag, a thrombopoietin receptor agonist, improved SAA …
Since the 1970s, hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy (IST) have changed SAA's natural …
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.
Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, Füreder W, Ptushkin V, Rottinghaus ST, Volles L, Shafner L, Aguzzi R, Pradhan R, Schrezenmeier H, Hill A. Lee JW, et al. Blood. 2019 Feb 7;133(6):530-539. doi: 10.1182/blood-2018-09-876136. Epub 2018 Dec 3. Blood. 2019. PMID: 30510080 Free PMC article. Clinical Trial.
Secondary end points were percent change from baseline in LDH, change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score, proportion of patients with breakthrough hemolysis, stabilized hemoglobin, and change in serum free C5. ...
Secondary end points were percent change from baseline in LDH, change from baseline in Functional Assessment of Chronic Illness Therapy
Long-term virological effectiveness with darunavir/ritonavir-based salvage therapy in people living with HIV/AIDS from Sao Paulo, Brazil.
Santos AMRD, Martins AP, Juliato D, de Miranda ÉJFP, Lopes GISL, Brígido LFM, Vidal JE. Santos AMRD, et al. Int J STD AIDS. 2020 Sep;31(10):967-975. doi: 10.1177/0956462420933716. Epub 2020 Jul 23. Int J STD AIDS. 2020. PMID: 32698729
Even though darunavir/ritonavir (DRV/r) has high potency and a greater genetic barrier, there are few studies on the long-term effectiveness of DRV/r-based salvage therapy in people living with HIV (PLWH) in low and middle-income countries. This retrospective cohort …
Even though darunavir/ritonavir (DRV/r) has high potency and a greater genetic barrier, there are few studies on the long-term effectiveness …
Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study.
Fernandez LM, São Julião GP, Figueiredo NL, Beets GL, van der Valk MJM, Bahadoer RR, Hilling DE, Meershoek-Klein Kranenbarg E, Roodvoets AGH, Renehan AG, van de Velde CJH, Habr-Gama A, Perez RO; International Watch & Wait Database Consortium. Fernandez LM, et al. Lancet Oncol. 2021 Jan;22(1):43-50. doi: 10.1016/S1470-2045(20)30557-X. Epub 2020 Dec 11. Lancet Oncol. 2021. PMID: 33316218
Surveillance of these patients is generally intensive, because local regrowth (with the potential for salvage) occurs in 25% of patients, and distant metastases occur in 10% of patients. ...
Surveillance of these patients is generally intensive, because local regrowth (with the potential for salvage) occurs in 25% of patie …
Outcomes and toxicity after salvage radiotherapy for vaginal relapse of endometrial cancer.
Sapienza LG, Ning MS, de la Pena R, McNew LK, Jhingran A, Georgeon L, Rasool N, Gomes MJL, Abu-Isa E, Baiocchi G. Sapienza LG, et al. Int J Gynecol Cancer. 2020 Oct;30(10):1535-1541. doi: 10.1136/ijgc-2020-001281. Epub 2020 May 5. Int J Gynecol Cancer. 2020. PMID: 32376738
OBJECTIVES: Studies of salvage radiotherapy in locally recurrent endometrial cancer remain limited. ...Patients should be closely monitored for late gastrointestinal toxicity following salvage radiotherapy....
OBJECTIVES: Studies of salvage radiotherapy in locally recurrent endometrial cancer remain limited. ...Patients should be closely mon …
Hip salvage surgery in cerebral palsy cases: a systematic review.
de Souza RC, Mansano MV, Bovo M, Yamada HH, Rancan DR, Fucs PM, Svartman C, de Assumpção RM. de Souza RC, et al. Rev Bras Ortop. 2015 Jun 16;50(3):254-9. doi: 10.1016/j.rboe.2015.06.003. eCollection 2015 May-Jun. Rev Bras Ortop. 2015. PMID: 26229926 Free PMC article. Review.
We conducted a systematic review of the literature to compare the results from the main hip salvage techniques applied to these individuals. The literature search focused on studies that evaluated results from hip salvage surgery in cases of cerebral palsy, publishe …
We conducted a systematic review of the literature to compare the results from the main hip salvage techniques applied to these indiv …
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N. Geoerger B, et al. Lancet Oncol. 2020 Jan;21(1):121-133. doi: 10.1016/S1470-2045(19)30671-0. Epub 2019 Dec 4. Lancet Oncol. 2020. PMID: 31812554 Clinical Trial.
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Dreyling M, Santoro A, Mollica L, Leppä S, Follows G, Lenz G, Kim WS, Nagler A, Dimou M, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Munoz J, Rodrigues L, Hiemeyer F, Miriyala A, Garcia-Vargas J, Childs BH, Zinzani PL. Dreyling M, et al. Am J Hematol. 2020 Apr;95(4):362-371. doi: 10.1002/ajh.25711. Epub 2020 Jan 16. Am J Hematol. 2020. PMID: 31868245 Free article.
331 results